Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EPR Properties (EPR) vs Viatris Inc (VTRS) Price & Performance

EPR PropertiesTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

EPR Properties vs Viatris Inc — how do they compare? EPR Properties trades at $60.94 (market cap $4.58B), while Viatris Inc trades at $16.11 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 4.1× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.22%). Which is the better fit depends on your goals.

EPRVTRS
Market Cap
$4.58B$18.69B
Sector
Real EstateHealth
52-Week High
$64.32$17.86
52-Week Low
$48.71$9.49
Enterprise Value
$8.09B$30.80B
Dividend Yield
6.22%2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EPR Properties

EPR Properties trades at $60.81, up 0.68% on the day, with a bearish technical signal but strong fundamentals including a 91.41% gross margin and recent Q2 2026 FFO beat. The company raised full-year guidance after deploying $440 million in investments at an 8.5% cap rate, signaling growth momentum. Dividend payments remain consistent at $0.31 monthly, supported by a conservative 65% AFFO payout ratio.

Outlook is mixed: analyst consensus is a Buy with a $65.30 target (7% upside), but technicals and some sentiment caution near-term. Key risks include theater exposure and rising interest rates. The stock offers a 6% yield with potential for dividend growth, balancing income and moderate appreciation prospects.

Viatris Inc

Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.

Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About EPR Properties

EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.

Read more on EPR

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS